RESUMEN
BACKGROUND: Several studies have evaluated the effects of zinc supplementation on glycemic biomarkers in humans and have demonstrated varying results. We systematically evaluated the literature and performed an umbrella meta-analysis of the effects of zinc supplementation on type 2 diabetes biomarkers. METHODS: A comprehensive literature search was conducted in the following databases; PubMed, Embase, Embase, Cochrane Library, Scopus, and Web of Science for studies published up to March 10, 2024. RESULTS: Zinc supplementation was effective in reducing serum FBS (WMD: - 13.58, 95% CI: - 17.38, - 9.77; p < 0.001; SMD: - 0.52, 95% CI - 0.79, - 0.25; p = < 0.001), insulin (SMD: - 0.67, 95% CI - 0.96, - 0.38; p < 0.001), HOMA-IR levels (WMD - 0.52, 95% CI - 0.66, - 0.38; p < 0.001; SMD: - 0.78, 95% CI - 1.02, - 0.42; p < 0.001), and HbA1c (WMD: - 0.35, 95% CI - 0.43, - 0.27; p < 0.001). CONCLUSION: Zinc supplementation significantly reduced FBS, HOMA-IR, insulin and HbA1c. These findings suggest that zinc is potentially an effective complementary intervention to improve type 2 diabetes biomarkers.
RESUMEN
ncRNAs, particularly miRNAs, lncRNAs and circRNAs, are a group of RNAs which, although they do not encode proteins (however, recent evidence shows that certain circRNAs are translatable), play a major role in regulating gene expression and, therefore, affect multiple cellular processes, in particular apoptosis. Apoptosis is proven to mediate myocardial infarction physiopathology in addition to ischemic necrosis and, therefore, has recently gained great interest as a target to improve MI outcomes. The current work reviews studies that have assessed ncRNAs with the ability to promote or suppress apoptosis in the process of MI and, therefore, may introduce new therapeutic targets for MI treatment.